InsiderTrades

Form 4 for CSTL CASTLE BIOSCIENCES INC

Accepted 2026-09-03 16:07:34 ET · period of report 2026-09-01 · accession 0001628280-26-060430 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-09-03 16:07 2026-09-01 CSTL Oelschlager Kristen M COO M - OptEx $3.38 +4,152 17.5K +31% +$14.0K
DMT 2026-09-03 16:07 2026-09-01 CSTL Oelschlager Kristen M COO S - Sale+OE $33.39 -4,152 13.4K -24% -$138.6K
DT 2026-09-03 16:07 2026-09-01 CSTL Oelschlager Kristen M COO M - OptEx $0.00 -4,152 12.5K -25% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-09-01 M A 4,152 $3.38 17,508 D — — (F1) These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, on March 17, 2026. (F2) Includes 68 shares acquired on August 31, 2026, under the Issuer's employee stock purchase plan.
2 Common Common Stock 2026-09-01 S D 3,952 $33.36 13,556 D — — (F1) These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, on March 17, 2026. (F3) This transaction was executed in multiple trades at prices ranging from $33.015 to $33.900, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3 Common Common Stock 2026-09-01 S D 200 $34.02 13,356 D — — (F1) These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, on March 17, 2026.
4 Derivative Stock option (right to buy) 2026-09-01 M D 4,152 $0.00 12,458 D $3.38 · — to 2029-03-12 4,152 Common Stock (F1) These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, on March 17, 2026. (F5) The shares subject to the option are fully vested.